Google
HAE Stock Analysis — HAEMONETICS CORPORATION (Healthcare >> Medical Devices)
HAE FAQ
What is HAE's P/E ratio?
HAEMONETICS CORPORATION (HAE) currently trades at a P/E ratio of 33.66.
What is HAE's ROE?
HAEMONETICS CORPORATION reports a Return on Equity (ROE) of 12.22%.
What is HAE's dividend yield?
HAEMONETICS CORPORATION offers a dividend yield of 0.00%.
What is HAE's Quality Score?
Our AI rates HAE's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy HAE?
Our AI Timing Score for HAE is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does HAE belong to?
HAEMONETICS CORPORATION is classified under the Healthcare >> Medical Devices sector on the NYSE exchange
HAE AI Analysis Summary
Our AI summary for HAE: HAEMONETICS CORPORATION (NYSE), Healthcare >> Medical Devices sector. The stock currently trades at a P/E of 33.66, ROE of 12.22%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 85.54
Price
0.72
(0.85%)
Day Change
|
|
|---|
HAE, the overall quality is not good ( Quality = 38) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
Acceleration of ROE growth rate is below our criteria.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
1734
|
| Magic Formula Rank by ROE |
1734
|
| Magic Formula Rank by ROIC |
1777
|
| Price | 85.54 |
| PBV / Sector |
4.97 / -101.57
|
| Earning Per Share | 2.05 |
| PE / Sector |
33.66 / 31.23
|
| PEG or PE/Growth / Sector |
1.45 / 0.40
|
| Average 1M Daily Value |
47.72 M
GREAT
|
| Average 1W Daily Value |
64.27 M
|
| Timing Factors |
|
85% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
62% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 07:59:56 |
| Symbol | HAE |
| Name | HAEMONETICS CORPORATION |
| Sector | Healthcare >> Medical Devices |
| Market | NYSE |
| Listed Shares | 45.45 M |
| Par Value | N/A |
| Calculated From | YearEnd |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 3,954.00 / 20,104.97 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 125 Summer Street, Boston, MA, United States, 02110
Phone: 781 848 7100
Website: https://www.haemonetics.com
Employees: 3,009
Sector: Healthcare >> Medical Devices
Description: Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Medical Devices
Click a bubble to view stock details · Bubble size represents market capitalization share
